PTC Therapeutics, Inc.
PTCT
$46.41
-$0.53-1.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -13.97% | 12.84% | 9.98% | 20.39% | 34.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.97% | 12.84% | 9.98% | 20.39% | 34.20% |
| Cost of Revenue | -19.15% | -23.03% | -23.41% | -12.59% | 6.66% |
| Gross Profit | 4.44% | 1,659.64% | 836.32% | 1,107.92% | 1,555.19% |
| SG&A Expenses | -9.51% | -16.18% | -13.86% | -6.11% | 2.01% |
| Depreciation & Amortization | -72.72% | -25.72% | 23.84% | 77.18% | 91.01% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.92% | -21.58% | -15.20% | -1.03% | 14.02% |
| Operating Income | 58.00% | 75.10% | 59.05% | 37.76% | 18.77% |
| Income Before Tax | 47.84% | 41.62% | 28.33% | -7.53% | -18.49% |
| Income Tax Expenses | 100.25% | 131.85% | 79.60% | -127.01% | -144.14% |
| Earnings from Continuing Operations | 42.02% | 29.38% | 22.41% | -1.40% | -12.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.02% | 29.38% | 22.41% | -1.40% | -12.09% |
| EBIT | 58.00% | 75.10% | 59.05% | 37.76% | 18.77% |
| EBITDA | 36.99% | 106.86% | 104.20% | 89.94% | 62.56% |
| EPS Basic | 43.52% | 31.42% | 25.00% | 2.62% | -7.52% |
| Normalized Basic EPS | 54.49% | 53.66% | 40.31% | 29.90% | 19.78% |
| EPS Diluted | 43.52% | 31.46% | 25.08% | 2.74% | -7.40% |
| Normalized Diluted EPS | 54.49% | 53.66% | 40.31% | 29.90% | 19.78% |
| Average Basic Shares Outstanding | 2.68% | 3.08% | 3.87% | 4.38% | 4.33% |
| Average Diluted Shares Outstanding | 2.68% | 3.08% | 3.87% | 4.38% | 4.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |